Fast Locator 2011-2012: Cangene bioPharma - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Fast Locator 2011-2012: Cangene bioPharma



CANGENE bioPharma, is a contract manufacturer, providing fill/finish and support services for over 30 years. Located in Baltimore, MD, USA, close to the FDA, CANGENE bioPharma is highly compliant, having successfully passed inspections from numerous regulatory agencies in the US, EU, and Japan.

CANGENE bioPharma’s fill/finish services include:

  • Vial filling (3cc-100cc) - batches up to 85,000 5cc vials
  • Lyophilization (2 x 240 sq ft lyophilizers)
  • Syringe filling – 0.5cc–20cc syringes
  • Terminal Sterilization – with steam

CANGENE bioPharma prides itself on providing outstanding and flexible support to its partner companies. From clinical through commercial launch, CANGENE bioPharma has the experience, knowledgeable personnel and involved management team to ensure our partners’ products proceed from project initiation through manufacturing quickly with an emphasis on exceptional quality.

CANGENE bioPharma provides services to a worldwide customer base, including large, small and virtual pharmaceutical and biotechnology companies. CANGENE bioPharma produces products that are distributed in over 50 countries by our clients.


Regions covered:

North America


Outsourcing services provided:

Development and Phase I/II CTM

  • Injectable products development

Commercial Manufacturing

  • Injectables

Analytical Services

  • Chemistry and stability
  • Microbiology

Website:

www.cangenebiopharma.com

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
26%
Attracting a skilled workforce
29%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
31%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns

Click here